CoChat
Sign Up
Cited by 148Antifungal resistance and susceptibilityNeutropenia and Cancer InfectionsImmunodeficiency and Autoimmune Disorders

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

Open access
Pagano, Livio, Busca, Alessandro, Candoni, Anna, Cattaneo, Chiara, Cesaro, Simone, Fanci, Rosa, Nadali, Gianpaolo, Potenza, Leonardo +27 more·2017·Blood Reviews
DOI 10.1016/j.blre.2016.09.002
Open this paper in CoChat — free accountOpen PDF

Abstract

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.blre.2016.09.002

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Among patients with documented MRSA infections, delays of > 24-48 hours until antibiotic administration are associated with increased mortality in some studies, but not in others.

    “Among patients with documented MRSA infections, delays of > 24-48 hours until antibiotic administration are associated with increased mortality in some studies (143-147), but not in others (148-154).”

    From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [152]

    The Myelodysplastic Syndromes section discusses susceptibility to bacterial and invasive fungal infections, while the additional-information table concerns fungal-infection risk factors. Searches for MRSA, delayed antibiotic administration, and mortality found no passage addressing the claimed mixed findings for delays of more than 24–48 hours. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 126

  1. Teo EC, Chew Y, Phipps C. A review of monoclonal antibody therapies in lymphoma. Crit Rev Oncol Hematol. 2016; 97:72-84.
  2. Stein BL, Gotlib J, Arcasoy M, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015;13:424-34
  3. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071-9
  4. Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61:324-31.
  5. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75
  6. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091-100.
  7. Omer AK, Ziakas PD, Anagnostou T, et al. Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience. Biol Blood Marrow Transplant 2013;19:1190-96
  8. Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014;20:872-80
  9. Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother.2011;55:1953-60
  10. Heimann SM, Vehreschild MJ, Cornely OA et al. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation. Eur J Haematol. 2015;94:526-31
  11. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? Clin Infect Dis. 2016;62:362-8.
  12. van der Linden JW, Arendrup MC, Melchers WJ, Verweij PE. Azole Resistance of Aspergillus fumigatus in Immunocompromised Patients with Invasive Aspergillosis. Emerg Infect Dis. 2016;22:158-9
  13. Wang E, Farmakiotis D, Yang D, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.J Antimicrob Chemother. 2015;70:2362-8
  14. Brüggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents Clin Infect Dis. 2009;48:1441-58.
  15. Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab. 2014;15:651-79
  16. Caira M, Candoni A, Verga L, et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica 2015; 100:284-92.
  17. Wang Y, Yang F, Shen Y et al. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2015;108(3): pii: djv342. doi: 10.1093/jnci/djv342. · DOI
  18. Vallabhaneni S, Chiller TM. Curr Rheumatol Rep. Fungal Infections and New Biologic Therapies 2016;18:29
  19. Maccioni F, Vetere S, De Felice C et al. Pulmonary fungal infections in patients with acute myeloid leukaemia: is it the time to revise the radiological diagnostic criteria? Mycoses. 2016;59:357-64
  20. Pagano L, Caira M, Valentini CG, Posterano B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Reviews 2010;24:51-61.
  21. Pagano L, Stamouli M, Tumbarello M, et al. Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM D registry. Br J Haematol 2015;170:434-9.
  22. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95:644-50.
  23. Nucci M, Anaissie E. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood 2014;124:3858-3869.
  24. Neofytos D, Lu K, Seung AH, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis 2013;75:144-9.
  25. Nicolle MC, Bénet T, Thiebaut A, et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica. 2011;96:1685-91.
  26. Hoenigl M, Strenger V, Buzina W, et al. European Organization for the Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother 2012;67:2029-33.
  27. Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005;19:545-50.
  28. Stanzani M, Lewis RE, Fiacchini M, et al. A Risk Prediction Score for Invasive Mold Disease in Patients with HMs. PLoS ONE 2013; 8:1-9.
  29. Berthelot P, Loulergue P, Raberin H, et al. Efficacy of environmental measures to decrease the risk of hospitalacquired aspergillosis in patients hospitalised in haematology wards. Clin Microbiol Infect 2006; 12:738-44.
  30. Fianchi L, Leone G, Posteraro B, et al. Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. Leuk Res 2012;36:331-33.
  31. Kontoyiannis DP, Georgiadou SP, Wierda WG, et al. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma.2013;54:1730-33
  32. Kotsianidis I, Bouchliou I, Nakou E, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009;23:510-8.
  33. Kiladjian JJ, Bourgeois E, Lobe I, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006;20:463-70
  34. Álvarez F, Fernández-Ruiz M, Aguado JM. Iron and invasive fungal infection. Rev Iberoam Micol. 2013;30:217-25.
  35. Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica 2012;97:1459-70
  36. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010;116:1485-94.
  37. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk- stratification and management. Am J Hematol. 2015 ;90:831-41
  38. Lortholary O Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011;17:1882- 89.
  39. Shiada A, Pagano L, Groll A, et al. European Confederation of Medical Mycology Working Group on Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67
  40. Herbrecht R, Caillot D, Cordonnier C, et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother. 2012;67:2731-38.
  41. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903.
  42. Lee JH, Jang JH, Park J, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica. 2011;96:1441-47.
  43. Merkel D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013;88:130-4.
  44. Falantes JF, Calderón C, Márquez-Malaver FJ, et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk. 2014;14:80-6.
  45. Ofran Y, Filanovsky K, Gafter-Gvili A, et al. Higher infection rate after 7-compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2015;15:e95-9.
  46. Chabrol A, Cuzin L, Huguet F, et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica. 2010;95:996-1003.
  47. Cattaneo C, Monte S, Algarotti A, et al. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). J Antimicrob Chemother. 2011 ;66:2140-5
  48. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843-9.
  49. Rijneveld AW, van der Holt B, Daenen SM, et al. HOVON Cooperative group. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukaemia up to the age of 40. Leukemia. 2011;25:1697-703.
  50. Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146:76-85.
  51. Daenen S, van der Holt B, Dekker AW, et al. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukaemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia. 2012;26:1726-9.
  52. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463-71.
  53. Hunault-Berger M, Leguay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011;96:245-52.
  54. Hunault-Berger M, Leguay T, Huguet F, et al. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. Am J Hematol. 2015;90:811-8.
  55. Barba P, Sampol A, Calbacho M, et al. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol. 2012;87:631-4.
  56. Kadia TM, Kantarjian HM, Thomas DA, et al. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015;90:120-4.
  57. Ribera JM, Oriol A, González M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87-95.
  58. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644-52.
  59. Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521-8.
  60. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-71.
  61. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66.
  62. Sun Y, Huang H, Chen J, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol. 2015;36:757-67.
  63. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96:748-57.
  64. Nosari AM, Pioltelli ML, Riva M, et al. Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience. Leuk Lymphoma. 2014;55:1844-8.
  65. Takaoka K, Nannya Y, Shinohara A, Arai S, Nakamura F, Kurokawa M. A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. Ann Hematol. 2014;93:1637-44.
  66. Teng JC, Slavin MA, Teh BW, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100:e462-6.
  67. Wongso D, Fuchs M, Plütschow A, et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. J Clin Oncol. 2013;31:2819-24.
  68. Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant. 2009;43:121-6.
  69. Offidani M, Corvatta L, Polloni C, et al. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma. 2011;52:776-85.
  70. Teh BW, Teng JC, Urbancic K, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100:e28-31.
  71. Li J, Li Y, Huang B, Zheng D, Chen M, Zhou Z. Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy. Cell Biochem Biophys. 2015;71:457-64.
  72. Liu J, Huang H, Li Y, et al. Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. Tumour Biol. 2016;37:7893-900
  73. Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107:1023-33.
  74. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27:136-41.
  75. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51.
  76. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807.
  77. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787-98.
  78. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low- dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
  79. Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2009;33:670-72.
  80. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843-44.
  81. Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155-57.
  82. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003;9:976-80.
  83. Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood. 2004;103:538-44.
  84. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473-79.
  85. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18:1332-39.
  86. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104:1094-99.
  87. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494-500.
  88. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841-51.
  89. Cortes JE, Kim DW, Kantarjian HM, Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486-92.
  90. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783-96.
  91. Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84:215-20.
  92. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-64.
  93. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-901.
  94. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703- 08. 100. Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. J Clin Oncol. 2015;33:2288-95. 101. Temeck BK, Venzon DJ, Moskaluk CA, Pass HI. Thoracotomy for pulmonary mycoses in non-HIV-immunosuppressed patients. Ann Thorac Surg. 1994;58:333-8. 102. Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014;9:331-9. 103. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143:1478-79. 104. Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014;2014. pii: bcr2014204950. doi: 10.1136/bcr-2014- 204950. 105. Chan JF, Chan TS, Gill H, et al. Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors. Emerg Infect Dis. 2015;21:1101-06. 106. Stansfield LC, Begna, K, Tosh P, et al. Mucormycosis in a patient treated with ruxolitinib. [e-letter]. Blood 2013;122: 3843-3844 (doi:10.1182/blood-2013-10-531103). · DOI
  95. Passweg JR, Baldomero H, Barder P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant. 2016. doi: 10.1038/bmt.2016.20. [Epub ahead of print] 110. · DOI
  96. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50:476-82. 111. Pagano L, Caira M, Nosari A, et al. Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study "Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne". Clin Infect Dis. 2007;45:1161- 70. 112. Markowski J, Helbig G, Widziszowska A, et al. Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients. Med Sci Monit. 2015;21:1173-80 113.
  97. Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19:745-51. 114. Srinivasan A, McLaughlin L, Wang C, et al. Early infections after autologous hematopoietic stem cell transplantation in children and adolescents: the St. Jude experience. Transpl Infect Dis. 2014;16:90-7. 115
  98. Sun Y, Meng F, Han M, et al. Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter Prospective Observational Study. Biol Blood Marrow Transplant. 2015;21:1117-26. 116. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clin Infect Dis. 2009;48:265-73. 117. Gil L, Styczynski J, Komarnicki M. Infectious Complication in 314 Patients after High- Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation: Risk Factors Analysis and Outcome. Infection. 2007;35:421-27. 118. Liu Y-C, Chien S-H, Fan N-W, et al. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. J Microbiol Immunol Infect. 2015.pii:S1684-1182(15)00026-2 119.
  99. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of Invasive Mold Infections in Allogeneic Stem Cell Transplant Recipients: Biological Risk Factors for Infection According to Time after Transplantation. Clin Infect Disease 2008;47:1041-50. 120. Parody R, Martino R, de la Cámara R, et al. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. Bone Marrow Transplant 2015;50:274-81 121.
  100. Montesinos P, Rodríguez-Veiga R, Boluda B, et al. Incidence and risk factors of post- engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. Bone Marrow Transplant 2015;50:1465-72 122.
  101. Atalla A, Garnica M, Maiolino A, Nucci M. Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis 2015;17:7-13. 123. Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009;44:361-70 124.
  102. Sucak GT, Yegin ZA, Özkurt ZN, et al. Iron Overload: Predictor of Adverse Outcome in Hematopoietic Stem Cell Transplantation. Transplant Proc 2010; 42:1841-48 125.
  103. Zaas AK, Liao G, Chien JW, et al. Plasminogen Alleles Influence Susceptibility to Invasive Aspergillosis. PLoS Genet 2008;4:e1000101 132.
  104. Cunha C, Aversa F, Romani L, Carvalho A. Human Genetic Susceptibility to Invasive Aspergillosis. PLoS Pathog 2013;9:e1003434 133.
  105. Van den Brink MRM, Velardi E, Perales M-A. Immune reconstitution following stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015;2015:215-9. 134. Corzo-Leon DE, Satin MJ, Soave R, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses 2015;58:325-36 135.
  106. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827-33. 136. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-38 137.
  107. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34: 115-21 138.
  108. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft- versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768-76 139.
  109. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997;90:2502-08. 140. Warris A, Klaassen CH, Meis JF, et al. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol. 2003;41:4101-06. 141.
  110. Jessica M. Valdez, Phillip Scheinberg, Neal S. Young,Thomas J. Walsh. Infections in Patients With Aplastic Anemia. Semin Hematol 2009, 46:269-276 142.
  111. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two Decades. Clin Infect Dis. 2011;52:726-735 143.
  112. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005;36(7):621-9. 144. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol. 2010;149:263-72 145.
  113. Hol JA, Wolfs TF, Bierings MB, et al. Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2014;49:95- 101. 146. Kobayashi R, Kaneda M, Sato T, Suzuki D, Ichikawa M, Ariga T. Evaluation of risk factors for invasive fungal infection after allogeneic stem cell transplantation in pediatric patients. J Pediatr Hematol Oncol. 2007;29:786-91 147.
  114. Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011;56:1092-7 148.
  115. Ozsevik SN, Sensoy G, Karli A, et al. Invasive fungal infections in children with hematologic and malignant diseases. J Pediatr Hematol Oncol 2015;37:e69-72 149.
  116. Sahbudak Bal Z, Yilmaz Karapinar D, Karadas N, et al. Proven and probable invasive fungal infections in children with acute lymphoblastic leukaemia: results from an university hospital, 2005-2013. Mycoses 2015;58:225-32 150.
  117. Sano H, Kobayashi R, Suzuki D, Kishimoto K, Yasuda K, Kobayashi K. Bacteremia during neutropenia is a predictive factor for invasive fungal infection in children. Pediatr Int 2013;55:145-50 151.
  118. Srinivasan A, Wang C, Srivastava DK, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:94-101 152.
  119. Villarroel M, Avilés CL, Silva P, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation. Pediatr Infect Dis J 2010;29:816-21 153. Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012;47:749-56 154.
  120. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000 Aug;110:273-84. 155. Castagnola E, Bagnasco F, Bandettini R, et al. Role of acute graft-versus-host disease in the risk of bacteremia and invasive fungal disease after allogeneic hemopoietic stem cell transplantation in children. Results from a single-center observational study. Biol Blood Marrow Transplant 2014;20:1068-73. 156. Stuehler C, Kuenzli E, Jaeger VK, et al. Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis. J. Infect. Dis. 2015;212:959-67 157.
  121. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-33 158.
  122. Panackal AA, Li H, Kontoyiannis DP, Mori M, et al. Geoclimatic Influences on Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2010; 50:1588-97. 159. Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol. 2006 Jan;132:138-54. 160. Maertens J, Donnelly P, Kibbler C et al. Primary Antifungal Prophylaxis. Proceeding of ECIL 5, September 19-21 2013, Juan Les Pins (France) www.kobe.fr/ecil/telechargements2013/ECIL5antifungalprophylaxis%2020062014Final.pdf 161. Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009;27:3849-54. 162. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:1487-98 163.
  123. Abdul Salam ZH, Karlin RB, Ling ML, Yang KS. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am J Infect Control. 2010; 38:e1-7 164.
  124. Ceesay MM, Desai SR, Berry L et al. A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients.Br J Haematol. 2015;168:219-29 165.
  125. Chan JF, Chan TS, Gill H et al. Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors. Emerg Infect Dis. 2015;21:1101-6 166.
  126. Girmenia C, Guerrisi P, Frustaci AM, et al. New category of probable invasive pulmonary aspergillosis in haematological patients. Clin Microbiol Infect. 2012;18:990-6. 168. Prigitano A, Venier V, Cogliati M, De Lorenzis G, Esposto MC, Tortorano AM. Azole- resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012. Euro Surveill. 2014;19:20747.

Cited by

Sorted by citations

Authors
Pagano, L., Busca, A., Candoni, A., Cattaneo, C., Cesaro, S., Fanci, R., Nadali, G., Potenza, L., Russo, D., Tumbarello, M., Nosari, A., Aversa, F., Lessi, F., Criscuolo, M., Farina, F., Tisi, M. C., Turri, G., Barone, A., Spolzino, A., Del Principe, M. I., Quinto, A. M., Di Blasi, R., Maracci, L., Nabergoj, M., Cambò, B., Pegoraro, A., Marchesi, F., Pascale, S., Passi, A., Carlisi, M., Polverelli, N., Beggia, B., Rambaldi, B., Prezioso, L., & Sanna, M.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
  • Azienda Ospedaliera Universitaria Integrata Verona (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • University of Modena and Reggio Emilia (IT)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • University of Parma (IT)
  • Azienda Ospedale - Università Padova (IT)
  • Azienda Ospedaliera San Gerardo (IT)
  • University of Cagliari (IT)
Corresponding author
Pagano, Livio
ORCID
Venue
Blood Reviews
Publisher
Elsevier BV
Published
2017-03
Volume
31
Issue
2
Pages
17-29
ISSN
0268-960X (ISSN-L)
DOI
10.1016/j.blre.2016.09.002
OpenAlex
W2519482734
Cited by
148
References
6
Citations by year
2026: 10 · 2025: 15 · 2024: 17 · 2023: 22 · 2022: 13 · 2021: 16 · 2020: 16 · 2019: 14 · 2018: 15 · 2017: 8 · 2016: 1
FWCI
1.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Blood Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
invasive fungal infections, hematologic malignancies, risk stratification, Aspergillus, Zygomycetes, Fusarium, candidemia, antifungal prophylaxis, hematopoietic stem cell transplantation, allogeneic transplantation, acute myeloid leukemia, neutropenia, immunocompromised patients
MeSH terms
Invasive Fungal Infections, Antineoplastic Combined Chemotherapy Protocols, Disease Susceptibility, Humans, Risk, Incidence, Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review